Qualigen Therapeutics, Inc. Co-operation between RAS-F series and AMG-510 and MRTX1133Preclinical Data Show Potential to Overcome Resistance to Key KRAS-G12C…
Amedisys Board Determines Optum Proposal Could Reasonably be Expectedto Result in a Superior Proposal Amedisys Engaging in Discussions with Optum…
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients…
- Trial includes high risk AML patients that have relapsed post allo-HSCT and are refractory to salvage therapy - NEXI-001…
Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive…
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to…
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development…
Media Release Efti plus pembrolizumab led to deep, durable responses, regardless of PD-L1 expression levels, and median Duration of Response…
Interim data presented at ASCO show early evidence of single agent activity with meaningful reduction of several target lesionsBased on…
This is the second deal announced between Rani and Celltrion, building upon a previously announced partnership for ustekinumab biosimilar for…